Company / EPS (Diluted)
Ligand Pharmaceuticals, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$2.94
FY2025
5-year range
-$1.98 / $31.85
FY2021-FY2025
Trend
+248.5%
vs FY2024
Sector context
#16 of 204
Health Care
What the data says
EPS (Diluted) changed +248% YoY in FY2025, a notable deviation from the 9-year average annual change of +654%.
Based on SEC 10-K filings.
2.94 in FY2025 with a 5-year CAGR of -13.2%. Top quartile in the Health Care sector.
Declined from $3.31 to $2.94 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -13.2%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 204This company $2.94 Sector average -$0.89
▼
+431.7% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 248.5% year-over-year.
- Ranks #16 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2021.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.94 | +248.5% |
| FY2024 | -$1.98 | -159.8% |
| FY2023 | $3.31 | +1938.9% |
| FY2022 | -$0.18 | -100.6% |
| FY2021 | $31.85 | +434.4% |
| FY2020 | $5.96 | +1024.5% |
| FY2019 | $0.53 | +762.5% |
| FY2018 | -$0.08 | -100.7% |
| FY2017 | $10.83 | +1833.9% |
| FY2016 | $0.56 | +1.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026